Table 3. Multivariate analysis for PFS and OS in pooled study population treated with FOLFIRINOX and FDR-GEM plus CAP.

PFS	Univariate analysis, HR (95% CI)	P	Multivariate analysis, HR (95% CI)	P
RegimenFOLFIRINOX vs.FDR-GEM plus CAP	0.41 (0.16–1.00)	0.04	0.27 (0.09–0.81)	0.02
Age≥60 vs. <60 years	0.92 (0.39–2.15)	0.84	0.29 (0.10–0.86)	0.03
Baseline CA 19-9≥UNL vs. <UNL	4.83 (0.65–36.01)	0.13	19.8 (1.92–203.84)	0.01
SexFemale vs. male	1.13 (0.48–2.63)	0.78	2.60 (0.95–7.11)	0.06
SurgeryYes vs. no	0.10 (0.03–0.31)	<0.001	0.05 (0.01–0.21)	<0.001
OS	Univariate analysis, HR (95% CI)	P	Multivariate analysis, HR (95% CI)	P
RegimenFOLFIRINOX vs.FDR-GEM plus CAP	0.56 (0.25–1.29)	0.12
Age≥60 vs. <60 years	1.17 (0.54–2.53)	0.70
Baseline CA 19-9≥UNL vs. <UNL	1.58 (0.59–4.25)	0.37	3.20 (1.11–9.19)	0.03
SexFemale vs. male	0.76 (0.34–1.71)	0.51
SurgeryYes vs. no	0.22 (0.10–0.52)	<0.001	0.15 (0.06–0.37)	<0.001

PFS: progression-free survival; OS: overall survival; HR: hazard ratio; CI: confidence interval; FDR, fixed-dose rate; GEM, gemcitabine; CAP, capecitabine; UNL: upper normal limit.